Q-omics provides the consensus-scored VPS4A profile across patient tissues and cancer cell-line models. VPS4A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, VPS4A is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, VPS4A protein abundance shows 20,220 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, and PDAC as cancer lineages where VPS4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS4A survival associations across molecular data types. VPS4A RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS4A RNA expression–survival associations across cancer types. High VPS4A expression shows unfavorable associations in BLCA, LUSC, LIHC and HNSC, but favorable associations in KIRP and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for VPS4A RNA expression.
This table summarizes VPS4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VPS4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS4A shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRP, LIHC, COAD and KIRC. The KIRP box plot shows higher VPS4A RNA expression in tumor versus normal tissue (log2 FC = +0.537, t-test p < 0.001).
This table shows molecular features associated with VPS4A in patient tissues and cancer cell lines. In patient samples, VPS4A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
